Halozyme Therapeutics said first-quarter 2026 revenue and earnings rose sharply, driven by continued royalty growth from its ENHANZE drug-delivery platform. The company also authorized a new $1 billion share repurchase program, signaling confidence in cash generation and capital returns.
Halozyme Therapeutics said first-quarter 2026 revenue and earnings rose sharply, driven by continued royalty growth from its ENHANZE drug-delivery platform. The company also authorized a new $1 billion share repurchase program, signaling confidence in cash generation and capital returns.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
